Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Inclusion Criteria: * 1 Subjects must have histological confirmation of relapsed or refractory Hodgkin lymphoma (HL). * 2 12 to 75 years of age. * 3 ECOG performance of less than 2. * 4 Life expectancy of at least 3 months. * 5 Subjects with lymphoma must have at least one measureable lesion \>1 cm as defined by lymphoma response criteria. * 6 Subjects must have received at least two lines of prior regimens without Anti-PD-1 antibody treatment history, and must be off therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months. * 7 Subjects must have adequate marrow, live, renal and heart functions. Exclusion Criteria: * 1 Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications. * 2 Serious uncontrolled medical disorders or active infections, pulmonary infection especially. * 3 Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1 month . * 4 Prior organ allograft. * 5 Women who are pregnant or breastfeeding. * 6 Women with a positive pregnancy test on enrollment or prior to nvestigational product administration. * 7 Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.